Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer
- 1 March 2005
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (4) , 555-563
- https://doi.org/10.1016/j.ejca.2004.11.021
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancyBritish Journal of Cancer, 2003
- ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor‐Receptor‐2 Tyrosine Kinase ActivityMicrocirculation, 2002
- VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences, 2002
- SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in miceThe FASEB Journal, 2002
- VEGF antagonistsExpert Opinion on Biological Therapy, 2001
- Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced CancerJournal of Clinical Oncology, 2001
- Angiogenesis in cancer and other diseasesNature, 2000
- The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical developmentJournal of Clinical Investigation, 1999
- Mechanisms of angiogenesisNature, 1997